Inhibikase Therapeutics, Inc.
IKT· Nasdaq
IKTInhibikase Therapeutics, Inc.
Filed Aug 16, 2021 · 10-Q · 47 days after period end · 0001564590-21-044637
| Metric | Q2 2021 | Q2 2020 |
|---|---|---|
| Revenue | $1.36M | $219.59K |
| Net Income | -$2.64M | -$421.87K |
| EPS Diluted | -$0.22 | -$0.05 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inhibikase Therapeutics, Inc. · CIK 1750149 · Engraved from SEC EDGAR
ended Jun 30, 2021 · filed Aug 16, 2021 · 47 d after period end
